Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH

16-02-2017 | Image

Figure 3: Structure of different types of T-cell-engaging antibodies.

BiTE® are constructed of single polypeptide chain that consists of two VL and VH pairs that recognize CD3 and CD19, respectively. DARTs are constructed of two separate, but paired, polypeptide chains, each comprising VL and VH regions that recognize different cell-surface molecules; the two polypeptide chains dimerize and are linked by interchain disulphide bridge, forming two functional VL–VH pairs that each comprise a VL from one polypeptide and a VH from the other. TandAb®are constructed of dimerized single polypeptide chains; each chain contains two different VL regions and two different VH regions, which upon dimerization, form four antigen-recognition sites for two different antigen (two VL–VH pairs; targeting CD19 and CD3 in this case). DARTs and TandAb® have longer half-life compared to BiTE® due to their structure. Abbreviations: BiTE®, bispecific T-cell engagers; DART, dual affinity retargeting antibody; TandAb®, tetravalent tandem diabody; VH, antibody heavy-chain variable region; VL, antibody light-chain variable region.

print
PRINT
Image Credits